SciELO - Scientific Electronic Library Online

 
vol.72 issue2Oral administration of intravenous preparation of Vitamin K for excessive anticoagulation due to warfarinNeuromyelitis optica with high aquaporin-4 expression and positive serum aquaporin-4 autoantibodies author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Medicina (Buenos Aires)

Print version ISSN 0025-7680

Abstract

MALBRAN, Alejandro; FERNANDEZ ROMERO, Diego S.  and  MENENDEZ, Alejandra. Hereditary angioedema: A therapeutic guide. Medicina (B. Aires) [online]. 2012, vol.72, n.2, pp.119-123. ISSN 0025-7680.

Hereditary angioedema (HAE) is a rare autosomal dominant disease, characterized by episodes of edema involving the skin, gastrointestinal tract and larynx. HAE has a historical asphyxia mortality of 15% to 50%. It is the consequence of functional C1 inhibitor deficiency. The identification of bradykinin as the principal mediator of the disease has lead to the development of new drugs for its treatment. HAE management and treatment are agreed by international consensus decision. A therapeutic guide for the treatment of the disease is important to improve diagnosis and treatment. We here describe the pharmacology of drugs available for the treatment of HAE in Argentina: plasma derived C1 Inhibitor, the bradykinin antagonist: icatibant, the attenuated androgen danazol and the anti-fibrinolytic agents epsilonaminocaproic acid and tranexamic acid. Furthermore, we describe drug use and adverse effects control, as well as the last international consensus document recommendations applicable to Argentina to conform a first guide to HAE treatment in our country.

Keywords : Hereditary angioedema; C1 inhibitor; Treatment guide.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License